Patient specific drug screening and biomarker research in pancreatic ductal adenocarcinoma using newly established tumoroids

Patient specific drug screening and biomarker research in pancreatic ductal adenocarcinoma using newly established tumoroids - Tumoroids

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00023315

Enrollment

Registered

2021-03-26

Start date

2021-01-01

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C25

Interventions

Group 1: This is an observational study. Tumor tissue and blood are taken during routine pathological tissue analysis and routine blood draw - an thereby do not cause any additional intervention. This

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: PDAC, sufficient tumor material during pathological processing available, written consent

Exclusion criteria

Exclusion criteria: tumor material too small in pathological processing, no written consent

Design outcomes

Primary

Measure	Time frame
the successful establishment of a reliable patient-derived PDAC tumoroid protocol and individual chemosensitivity testing protocols	—

Secondary

Measure	Time frame
correlation of liquid biopsy mutation status results, tumoroid drug response and the patients' response to chemotherapeutic treatment	—

Countries

Germany

Contacts

Public ContactChristine Nitschke

Klinik für Allgemein-, Viszeral und ThoraxchirurgieUniversitätsklinikum Hamburg-Eppendorf

c.nitschke@uke.de04074100

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026